VAX-ID™皮内注射乙型肝炎加强疫苗的免疫原性与安全性
该概念验证研究纳入48名既往乙型肝炎免疫健康者,比较肌内注射与Mantoux皮内注射及VAX-ID™皮内注射乙型肝炎加强疫苗的免疫原性和安全性。所有受试者第14天均出现回忆应答,皮内组第14天和第30天免疫应答较肌内组高3倍,局部不良事件皮内组更多。VAX-ID™是皮内接种的可行替代方案。
要点
- 所有受试者加强后14天均出现回忆应答,抗体滴度持续至210天。
- 皮内组第14天和第30天免疫应答较肌内组高3倍。
- 皮内组局部不良事件报告多于肌内组。
核心结论
- VAX-ID™皮内注射装置被证明是提供皮内接种的良好替代方案。
研究设计与样本
- 概念验证研究纳入48名健康乙型肝炎既往免疫受试者,比较4组接种方式:三角肌标准肌内注射HBVAXPRO® 10 µg/1 ml、前臂近端后侧Mantoux技术皮内注射、单前臂VAX-ID™皮内注射、双前臂VAX-ID™皮内注射。
- 皮内注射从HBVAXPRO® 40 µg/1 ml药瓶抽取0.11 cc(其中0.01 cc为过量填充),在第0、14、30和210天随访免疫原性与安全性。
主要发现
- 所有受试者在加强接种后14天显示回忆应答,升高滴度持续至随访结束第210天。
- 皮内组在第14天和第30天记录的免疫应答较肌内组高3倍。
- 皮内组局部不良事件报告多于肌内组。
临床怎么用
- VAX-ID™可作为皮内接种乙型肝炎加强疫苗的替代装置,但需注意皮内组局部不良事件更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although intramuscular (IM) injection is still the most preferred method for vaccination, intradermal (ID) delivery may have several advantages over intramuscular and subcutaneous (SC), including an improved immune response and antigen dose sparing effect. However it is currently limited due to the difficulty in standardizing the injection technique often based on the Mantoux technique. Difficulties encountered using the Mantoux technique could be overcome by the use of alternative ID delivery systems that confer more uniform and standardized procedures. The aim of this study was to evaluate the performance of a newly developed intradermal injection device, VAX-ID™, via a proof-of-concept to assess the immunogenicity of a commercially available hepatitis B booster vaccination in healthy hepatitis B pre-immunised subjects. Additionally, device safety and tolerability was evaluated. MATERIALS AND METHODS: Three different routes of administration were compared over 4 groups, each receiving hepatitis B vaccine antigen: (1) standard IM injection in the deltoid region (HBVAXPRO® 10 µg/1 ml), (2) ID injection in the proximal posterior area of the forearm according to the Mantoux technique, (3) with VAX-ID™ in one forearm, or (4) with VAX-ID™ in both forearms. For ID injections 0.11 cc, of which 0.01 cc is overfill, was drawn from a vial containing HBVAXPRO® 40 µg/1 ml. Immunogenicity and safety were followed-up at day 0, 14, 30 and 210. RESULTS: A total of 48 subjects were included. All subjects showed an anamnestic response at 14 days post booster vaccination. Elevated titres persisted until end of follow-up at day 210. For the ID groups a 3 fold higher immune response at day 14 and day 30 was recorded compared to IM group. Local adverse events were more reported for ID compared to IM. CONCLUSIONS: The investigated ID injection device VAX-ID™ proves to be a good alternative to offer ID vaccination.
引用
- Van Mulder TJS, Withanage K, Beyers KCL, et al. Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID™. Vaccine. 2018. PMID: 30587432. doi:10.1016/j.vaccine.2018.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。